

Clinical Trial Protocol

Iranian Registry of Clinical Trials

01 Jul 2026

Evaluation of the effect of two herbal products (blend of vinegar, *Plantago ovata* and cotton) in comparison with placebo in patients with standard treatment of leishmaniasis in rural type center.

Protocol summary

Study aim

Evaluation of the effect of two herbal products (blend of vinegar, *Plantago ovata* and cotton) in comparison with placebo in patients with standard treatment of leishmaniasis in rural type center.

Design

A phase 3 clinical trial with a control group, with parallel, double-blind and randomized groups. Simple random by envelope method. Each group has 44 people. Total 132 people.

Settings and conduct

After approval of herbs and toxicological and microbial tests, medicines are given to patients in similar forms. Patients and health care providers are not aware of the drug content. Full patient and wound characteristics are recorded. Before the start of treatment, the end of the first, second, third, fourth and eighth weeks of wound healing and clinical information (including wound size, induration size, and epithelialization rate) will be measured and recorded. Patients will be taken in Yazd and Ardakan centers.

Participants/Inclusion and exclusion criteria

Inclusion criteria: Test positive, age between 6 and 60 years, wound diameter less than 3 cm, 4 lesions and less. Exclusion criteria: Complicated Types, 5 Lesions and Over, Wound Diameter Over 3cm, Lactating and Pregnant Women, Facial Wounds, Sensitivity to Glucantime, Onset of More Than 3 Months, Use of Other Anti-leishmaniasis Medications in the Past Month.

Intervention groups

Patients were randomly divided into three groups of 44 patients. Patients are randomly assigned to one of the following study groups: 1- The group receiving the composition of vinegar and *plantago ovata*. 2- Receiving group of cotton plant product. 3. Control group. All patients will receive standard treatment for cutaneous leishmaniasis based on the latest national guidelines.

Main outcome variables

The surface of the wound

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20191221045845N1**

Registration date: **2020-01-29, 1398/11/09**

Registration timing: **registered_while_recruiting**

Last update: **2020-01-29, 1398/11/09**

Update count: **0**

Registration date

2020-01-29, 1398/11/09

Registrant information

Name

Sayed Mehrdad Mousavi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 35 3223 8916

Email address

sm.mousavi@stu.ssu.ac.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2020-01-15, 1398/10/25

Expected recruitment end date

2020-04-20, 1399/02/01

Actual recruitment start date

empty

Actual recruitment end date

empty
Trial completion date
empty

Scientific title
Evaluation of the effect of two herbal products (blend of vinegar, Plantago ovata and cotton) in comparison with placebo in patients with standard treatment of leishmaniasis in rural type center.

Public title
The effect of medicinal plants on the leishmaniosis

Purpose
Treatment

Inclusion/Exclusion criteria

Inclusion criteria:

Proof of cutaneous leishmaniasis through smear The patients should not be less than 6 years old and not more than 60 years old The lesion size should be less than 3 cm The duration of the illness is less than 12 weeks No lesion on the face Not having any other anti-leishmaniasis medication in the past 4 weeks Don't be pregnant or breastfeeding Do not have severe skin disease such as eczema, psoriasis or chronic dermatitis of unknown origin Has no serious, chronic or malignant disease and is not under chemotherapy treatment Has 4 or less lesions in the body No travel history 6 months ago

Exclusion criteria:

The type of cutaneous leishmaniasis may be complicated, with complications such as a patient with mucosal leishmaniasis Having 5 lesions and more Lesions greater than 3 cm Subcutaneous nodules Regional adenopathy larger than 1 cm People with immunodeficiency Children under 6 years Women in Lactation and Pregnancy sporotrichoid leishmaniasis or satellite lesions Patients with ulcers on the face Patients with a history of drug allergy to antimony compounds Patients who have had more than three months since their first skin lesions appeared Patients who have used any method of treatment for cutaneous leishmaniasis during the past month Patients with a history of travel to other areas of leishmaniasis in the past 6 months as well as those of urban leishmaniasis

Age
From **6 years** old to **60 years** old

Gender
Both

Phase
2-3

Groups that have been masked

- Participant
- Care provider

Sample size
Target sample size: **132**
More than 1 sample in each individual
Number of samples in each individual: **3**
wound

Randomization (investigator's opinion)
Randomized

Randomization description
Simple randomization envelopes shuffling

Blinding (investigator's opinion)

Double blinded

Blinding description

To blind the participants and the clinical caregiver, the drugs are labeled with codes 1, 2, and 3 (placebo). The patient and the clinical caregiver and principal investigator are unaware of the type of drug.

Placebo

Used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

Ethics committee of yazd University of Medical Sciences

Street address

school of Iranian Medicine, Imam Khomeini street, ardekan, yazd

City

yazd

Province

Yazd

Postal code

8951737915

Approval date

2019-10-08, 1398/07/16

Ethics committee reference number

IR.SSU.REC.1398.136

Health conditions studied

1

Description of health condition studied

Cutaneous leishmaniasis

ICD-10 code

B55.1

ICD-10 code description

Cutaneous leishmaniasis

Primary outcomes

1

Description

Leishmaniasis lesion area

Timepoint

Before treatment and then every week until healing or the eighth week

Method of measurement

Mathematical calculations with mm-square scale

Secondary outcomes

sm.mousavi@stu.ssu.ac.ir

1

Description

Wound healing time

Timepoint

End of treatment

Method of measurement

Time between start and end of treatment in days

Intervention groups

1

Description

Intervention group: Standard treatment plus cream (topical medicinal product) containing extract of cotton plant is administered twice daily for 8 weeks.

Category

Treatment - Drugs

2

Description

Intervention group: Standard treatment plus cream (topical medicinal product) containing the combination of plantago ovata and vinegar is given twice daily for 8 weeks.

Category

Treatment - Drugs

3

Description

Control group: Standard treatment plus placebo is given twice daily for 8 weeks.

Category

Treatment - Other

Recruitment centers

1

Recruitment center

Name of recruitment center

Yazd University of Medical Sciences

Full name of responsible person

Sayed Mehrdad Mousavi

Street address

imam khomeini

City

Ardekan

Province

Yazd

Postal code

8951737915

Phone

+98 35 3223 8917

Fax

+98 31 3223 8915

Email

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Yazd University of Medical Sciences

Full name of responsible person

majid emtiazy

Street address

school of iranian medicine, Imam Khomeini Ave,Ardekan.

City

yazd

Province

Yazd

Postal code

8951737915

Phone

+98 35 3223 8917

Fax

+98 35 3223 8915

Email

dr.emtiazy@yahoo.com

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Yazd University of Medical Sciences

Proportion provided by this source

100

Public or private sector

Public

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

Academic

Person responsible for general inquiries

Contact

Name of organization / entity

Yazd University of Medical Sciences

Full name of responsible person

Majid Emtiazy

Position

Assistant Professor

Latest degree

Ph.D.

Other areas of specialty/work

Traditional Medicine

Street address

school of iranian medicine, Imam Khomeini Ave,Ardekan.

City

Ardekan
Province
Yazd
Postal code
8951737915
Phone
+98 35 3223 8915
Fax
+98 35 3223 8915
Email
dr.emtiaz@yahoo.com

Person responsible for scientific inquiries

Contact

Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Mohammad Ebrahimzade
Position
Assistant Professor
Latest degree
Specialist
Other areas of specialty/work
Dermatology
Street address
Yazd University of Medical Sciences
City
yazd
Province
Yazd
Postal code
8916978477
Phone
03537240171-5
Email
mohammad110eb@yahoo.com

Person responsible for updating data

Contact

Name of organization / entity
Yazd University of Medical Sciences
Full name of responsible person
Sayed Mehrdad Mousavi
Position
University student
Latest degree

Medical doctor
Other areas of specialty/work
General Practitioner
Street address
Imam Khomeini Ave, school of Iranian Medicine
City
Ardekan
Province
Yazd
Postal code
8951737915
Phone
03532238916-7
Email
dr_smmd@yahoo.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Yes - There is a plan to make this available

Study Protocol

Yes - There is a plan to make this available

Statistical Analysis Plan

Yes - There is a plan to make this available

Informed Consent Form

Yes - There is a plan to make this available

Clinical Study Report

Yes - There is a plan to make this available

Analytic Code

Yes - There is a plan to make this available

Data Dictionary

Yes - There is a plan to make this available

Title and more details about the data/document

Monitoring information during the study

When the data will become available and for how long

Upon first request or about a week

To whom data/document is available

Applicant's subordinate authorities

Under which criteria data/document could be used

Proof, Understanding and Exploitation

From where data/document is obtainable

Person responsible for updating information

What processes are involved for a request to access data/document

Request the person responsible for the public accountability of the trial

Comments

-